You are here

Aimmune Therapeutics

A Tale of 2 Biotechs With Competing Peanut Allergy Treatments

A Tale of 2 Biotechs With Competing Peanut Allergy Treatments

Motley Fool

DBV Technologies

Aimmune Therapeutics

Flag link:

Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing

Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing

Xconomy

Aimmune Therapeutics

drug manufacturing

Flag link:

Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Motley Fool

Aimmune Therapeutics

Flag link:

Aimmune Presents New Peanut Allergy Data and Presses for Real-World Data Approaches

Aimmune Presents New Peanut Allergy Data and Presses for Real-World Data Approaches

BioSpace

Aimmune Therapeutics

real world data

Flag link:

Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug

Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug

NPR

Aimmune Therapeutics

Flag link:

An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening

An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening

Stat

advisory panels

Aimmune Therapeutics

Flag link:

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

Endpoints

Aimmune Therapeutics

DBV Technologies

Flag link:

Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

Motley Fool

Aimmune Therapeutics

Flag link:

FDA schedules Aimmune's peanut allergy drug for September expert review

FDA schedules Aimmune's peanut allergy drug for September expert review

Biopharma Dive

Aimmune Therapeutics

Flag link:

4 Blockbuster Drug Launches to Watch in 2019

4 Blockbuster Drug Launches to Watch in 2019

Motley Fool

Alexion Pharmaceuticals

Aimmune Therapeutics

rheumatoid arthritis

Flag link:

Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear

Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear

BioSpace

Aimmune Therapeutics

Flag link:

[audio+transcript] 6 Biotech Stocks to Watch Now

[audio+transcript] 6 Biotech Stocks to Watch Now

Motley Fool

Global Blood Therapeutics

Aimmune Therapeutics

Vertex Pharmaceuticals

Sarepta Therapeutics

Flag link:

3 Potential New Drugs Held Up by the Shutdown

3 Potential New Drugs Held Up by the Shutdown

Motley Fool

government shutdown

Aimmune Therapeutics

Bristol-Myers Squibb

Flag link:

FDA’s Gottlieb Adds Confusion to Aimmune’s Claims of Shutdown Delay

FDA’s Gottlieb Adds Confusion to Aimmune’s Claims of Shutdown Delay

Xconomy

Aimmune Therapeutics

government shutdown

Flag link:

Aimmune says shutdown blocks peanut allergy drug review

Aimmune says shutdown blocks peanut allergy drug review

Fierce Biotech

Aimmune Therapeutics

government shutdown

Flag link:

Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts

Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts

Endpoints

Aimmune Therapeutics

Flag link:

Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies

Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies

Endpoints

Aimmune Therapeutics

Flag link: